Connect your AI

PTHS PTHS Finished goods

Finished goods at other companies

Cumberland PharmaceuticalsCPIX

$5.27M+75.1%

Zevra Therapeutics, Inc.ZVRA

$1.44M—

HRO

HarrowHROW

$8.43M+54.5%

Arcutis Biotherapeutics, Inc.ARQT

$14.68M+77.5%

LifeMD, Inc.LFMD

$2.43M+9.9%

ExelixisEXEL

——

Other financials

Income statement

Revenue$10.9M—

Gross profit$9.2M—

Operating income-$13.1M-614%

Net income-$10.2M-420%

EPS (diluted)-$3.09+3.7%

Balance sheet

Cash & equivalents$32.0M+24,250%

Total debt$29.6M—

Total equity$35.1M+937%

Total assets$145.4M+15,855%

Cash flow

Operating cash flow-$13.1M-1,977%

CapEx$194.0K—

Free cash flow-$13.3M-2,008%

Valuation

Market cap$98.22M+75.4%

Enterprise value$95.89M—

P/S3.6×—

Profitability

Gross margin79.6%—

Operating margin-157.7%—

Net margin-186.2%—

FCF margin-60.8%—

Returns & leverage

Return on equity-333.8%—

Debt / equity0.8×—

Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:InventoryFinishedGoodsNetOfReserves.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's finished goods.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is PTHS's finished goods?: PTHS (PTHS) reported finished goods of $8.7M in Q1 2026.
What does finished goods mean?: Completed products ready for sale, valued at the lower of cost or net realizable value.